Evidence map›Paper›PMID 38432214›Full record

ArticleCardiology2024

Association of Circulating Autophagy Proteins ATG5 and Beclin 1 with Acute Myocardial Infarction in a Case-Control Study.

Marie-Hélène Grazide, Jean-Bernard Ruidavets, Wim Martinet, Meyer Elbaz, Cécile Vindis

Open access · hybridAbstract read
In one paragraph

Article in Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. The role of autophagy in pancreatic diseases.Frontiers in pharmacology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Marie-Hélène GrazideCenter for Clinical Investigation (CIC1436)/CARDIOMET, Rangueil University Hospital, Toulouse, France.
Jean-Bernard RuidavetsDepartment of Epidemiology, INSERM UMR 1027, Toulouse, France.
Wim MartinetLaboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
Meyer ElbazCenter for Clinical Investigation (CIC1436)/CARDIOMET, Rangueil University Hospital, Toulouse, France.
Cécile VindisCenter for Clinical Investigation (CIC1436)/CARDIOMET, Rangueil University Hospital, Toulouse, France.
Hôpital Rangueil · FRInserm · FRUniversité Toulouse III - Paul Sabatier · FRUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute myocardial infarction (AMI) is a main contributor of sudden cardiac death worldwide. The discovery of new biomarkers that can improve AMI risk prediction meets a major clinical need for the identification of high-risk patients and the tailoring of medical treatment. Previously, we reported that autophagy a highly conserved catabolic mechanism for intracellular degradation of cellular components is involved in atherosclerotic plaque phenotype and cardiac pathological remodeling. The crucial role of autophagy in the normal and diseased heart has been well described, and its activation functions as a pro-survival process in response to myocardial ischemia. However, autophagy is dysregulated in ischemia/reperfusion injury, thus promoting necrotic or apoptotic cardiac cell death. Very few studies have focused on the plasma levels of autophagy markers in cardiovascular disease patients, even though they could be companion biomarkers of AMI injury. The aims of the present study were to evaluate (1) whether variations in plasma levels of two key autophagy regulators autophagy-related gene 5 (ATG5) and Beclin 1 (the mammalian yeast ortholog Atg6/Vps30) are associated with AMI and (2) their potential for predicting AMI risk.

methodsThe case-control study population included AMI patients (n = 100) and control subjects (n = 99) at high cardiovascular risk but without known coronary disease. Plasma levels of ATG5 and Beclin 1 were measured in the whole population study by enzyme-linked immunosorbent assay.

resultsMultivariate analyses adjusted on common cardiovascular factors and medical treatments, and receiver operating characteristic curves demonstrated that ATG5 and Beclin 1 levels were inversely associated with AMI and provided original biomarkers for AMI risk prediction.

conclusionPlasma levels of autophagy regulators ATG5 and Beclin 1 represent relevant candidate biomarkers associated with AMI.

Indexed as

AutophagyAutophagy-Related Protein 5Beclin-1BiomarkersMyocardial InfarctionAgedCase-Control StudiesFemaleHumansMaleMiddle AgedATG5 protein, humanAutophagy-Related Protein 5Beclin-1BECN1 protein, humanBiomarkersAcute myocardial infarctionATG5AutophagyBeclin 1BiomarkerRisk prediction

Identifiers

PMID38432214
PMCPMC11152019
OpenAlexW4393165501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.